S. Singhal

S. Singhal, P. Vanamail, D. Deka, 2019, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.

S. Singhal, Rashmi Kumar, C. Huff, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants.

S. Singhal, J. Mehta, B. Sirohi, 2000, Blood.

Primary HPV screening for cervical cancer.

S. Singhal, N. Bhatla, 2020, Best practice & research. Clinical obstetrics & gynaecology.

F‐18 FDG‐PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem‐cell transplantation for relapsed and refractory Hodgkin lymphoma

B. B. Weitner, L. Gordon, J. Winter, 2014, British journal of haematology.

Evaluation of prevalence and prognostic significance of human epidermal growth factor receptor 2/neu expression in carcinoma endometrium

S. Singhal, Neeta Singh, D. Sharma, 2020 .

Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA-identical sibling.

S. Singhal, J. Mehta, R. Powles, 1999, Leukemia & lymphoma.

Clinical significance of non‐Candida fungal blood isolation in patients undergoing high‐risk allogeneic hematopoietic stem cell transplantation (1993–2001)

S. Singhal, J. Mehta, A. Safdar, 2004, Cancer.

Minimal Invasive Surgery for Management of Endometrial Cancer

S. Singhal, Sarika Gupta, 2020 .

estimation in patients with plasma cell dyscrasias The serum-free light chain assay cannot replace 24-hour urine protein

S. Singhal, J. Mehta, R. Stein, 2011 .

The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias.

S. Singhal, J. Mehta, R. Stein, 2007, Blood.

Myeloma Is Characterized by Stage-Specific Alterations in DNA Methylation That Occur Early during Myelomagenesis

Joseph D Tariman, S. Singhal, J. Mehta, 2013, The Journal of Immunology.

Ascorbic-acid-induced haemolysis in G-6-PD deficiency

S. Singhal, J. Mehta, B. Mehta, 1990, The Lancet.

Role of phosphorylated insulin-like growth factor-binding protein-1 and cervical length measurements in predicting pre-term delivery

S. Singhal, A. Agarwal, Nivedita Sarda, 2014 .

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

C. Hofmeister, A. Krishnan, S. Singhal, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Hyperviscosity syndrome in plasma cell dyscrasias.

S. Singhal, J. Mehta, 2003, Seminars in thrombosis and hemostasis.

A Prospective Randomized Study Comparing Unipolar Versus Bipolar Hysteroscopic Myomectomy in Infertile Women

S. Singhal, P. Vanamail, K. Roy, 2017, Journal of human reproductive sciences.

FDA Policies Should Be Amended To Allow Pharmaceutical Manufacturers To Disseminate Information Regarding Potentially Fatal Toxicities That Occur with Off-Label Use of Oncology Agents: A Policy Recommendation Based on Review of Thalidomide-Associated Thromboembolism Cases by the RADAR Project.

S. Singhal, J. Mehta, P. Yarnold, 2004 .

Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy

B. Barlogie, S. Singhal, J. Mehta, 1999, Bone Marrow Transplantation.

relapsed, refractory multiple myeloma Clinical factors predictive of outcome with bortezomib in patients with

D. Esseltine, B. Barlogie, S. Jagannath, 2013 .

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

Joseph D Tariman, S. Lonial, N. Munshi, 2007, Blood.

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.

D. Esseltine, B. Barlogie, S. Jagannath, 2005, Blood.

Bortezomib in recurrent and/or refractory multiple myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2005, Cancer.

Hematopoietic growth factors pass through the blood–brain barrier in intact rats

D. Groothuis, S. Singhal, J. Mehta, 2007, Experimental Neurology.

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone

B. Barlogie, S. Jagannath, S. Singhal, 2000, Bone Marrow Transplantation.

Recurrent Endometrial Cancer

S. Singhal, A. Kaundal, 2020, Recent Advances in Endometrial Cancer.

Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft

S. Singhal, J. Mehta, B. Sirohi, 2005, Hematology.

Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.

B. Barlogie, S. Jagannath, D. Siegel, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic Light Chain Amyloidosis - Panel Members

A. Krishnan, S. Singhal, C. Huff, 2014 .

Easy to see but hard to find.

S. Singhal, J. Mehta, 2003, The New England journal of medicine.

Peritoneal metastasis in Stage IB1 adenocarcinoma cervix: A rare entity

S. Singhal, D. Sharma, S. Mathur, 2019, Journal of cancer research and therapeutics.

Reimmunization after blood or marrow stem cell transplantation

S. Singhal, J. Mehta, 1999, Bone Marrow Transplantation.

Review Reimmunization after blood or marrow stem cell transplantation

S. Singhal, J. Mehta, 1999 .

Primary thyroid lymphoma

S. Singhal, H. Dua, A. Amar, 2019 .

A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results.

S. Jagannath, S. Singhal, P. Richardson, 2005 .

Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype

Robin L. Jones, G. Morgan, S. Singhal, 2008, Leukemia & lymphoma.

Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes?

S. Singhal, J. Mehta, B. Sirohi, 2003, Bone Marrow Transplantation.

Hematopoietic growth factors pass through the brain-blood barrier in intact rats

D. Groothuis, S. Singhal, Li-Ru Zhao, 2011 .

Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

L. Gordon, J. Winter, S. Singhal, 2006, Bone Marrow Transplantation.

Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an ‘operational cure’?

S. Singhal, J. Mehta, B. Sirohi, 2000, Bone Marrow Transplantation.

Stem cell transplantation for multiple myeloma-10 years later

B. Barlogie, S. Jagannath, D. Siegel, 2000 .

Role of CD34+ cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue.

S. Singhal, J. Mehta, D. Catovsky, 1996, Bone Marrow Transplantation.

Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia

S. Singhal, J. Mehta, B. Sirohi, 2002, Bone Marrow Transplantation.

Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial

S. Singhal, J. Mehta, D. Tait, 2000, The Lancet.

Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukaemia due to reinfusion of a higher number of malignant cells.

S. Singhal, J. Mehta, R. Powles, 1995, Bone marrow transplantation.

Epigenomic Profiling of Multiple Myeloma Shows Widespread Stage Specific Alterations In DNA Methylation That Occur Early During Myelomagenesis

S. Singhal, J. Mehta, A. Verma, 2010 .

Instability of immunophenotype in plasma cell myeloma.

S. Singhal, J. Mehta, L. Peterson, 2008, American journal of clinical pathology.

Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation

S. Singhal, J. Mehta, B. Sirohi, 2000, Bone Marrow Transplantation.

Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.

S. Singhal, J. Mehta, J. Treleaven, 1996, Bone marrow transplantation.

Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome

S. Singhal, J. Mehta, A. Safdar, 2001, Bone Marrow Transplantation.

Melphalan/TBI is not more carcinogenic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years

S. Singhal, J. Mehta, D. Tait, 2000, Bone Marrow Transplantation.

Extended follow‐up of a phase II trial in relapsed, refractory multiple myeloma:

B. Barlogie, S. Jagannath, S. Singhal, 2006, Cancer.

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

D. Esseltine, B. Barlogie, S. Jagannath, 2006, Haematologica.

Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies

S. Singhal, J. Mehta, R. Powles, 1997, Bone Marrow Transplantation.

A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM).

K. Anderson, A. Jakubowiak, A. Krishnan, 2006 .

of the International Myeloma Workshop Consensus Panel 3 Consensus recommendations for standard investigative workup: report

S. Jagannath, J. Miguel, N. Munshi, 2012 .

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m2 Expansion Cohort of PX-171-007

D. Siegel, S. Singhal, K. Papadopoulos, 2011 .

Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis

S. Jagannath, A. Jakubowiak, S. Lonial, 2011 .

Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients

S. Singhal, J. Mehta, A. Gee, 2004, Bone Marrow Transplantation.

Haploidentical vs autologous hematopoietic stem cell transplantation in patients with acute leukemia beyond first remission

S. Singhal, J. Mehta, B. Sirohi, 2003, Bone Marrow Transplantation.

The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia.

S. Singhal, J. Mehta, D. Tait, 2002, Blood.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

D. Esseltine, B. Barlogie, S. Jagannath, 2005, Blood.

Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation?

L. Gordon, J. Winter, S. Singhal, 2004, Bone Marrow Transplantation.

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.

G. Morgan, J. San Miguel, P. Sonneveld, 2003, The hematology journal : the official journal of the European Haematology Association.

Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy

S. Singhal, J. Mehta, Eric Vickrey, 2009, Cancer.

The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients

G. Morgan, S. Singhal, J. Mehta, 2008, Bone Marrow Transplantation.

The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy.

S. Singhal, J. Mehta, T. Min, 1999, Leukemia & lymphoma.

Feasibility of laparoscopy in management of ectopic pregnancy: experience from a tertiary care hospital

S. Singhal, K. Roy, Sunesh Kumar, 2018 .

Impact of previous high-dose therapy on outcome after allografting for multiple myeloma

S. Singhal, J. Mehta, D. Tait, 1999, Bone Marrow Transplantation.

Graft-versus-myeloma

S. Singhal, J. Mehta, 1998, Bone Marrow Transplantation.

Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?

B. Barlogie, S. Jagannath, S. Singhal, 1998, Bone Marrow Transplantation.

A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold?

S. Singhal, J. Mehta, D. Tait, 2000, Bone Marrow Transplantation.

Relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings.

S. Singhal, J. Mehta, R. Powles, 1995, Bone marrow transplantation.

xerostomia associated with chronic graft-versus-host disease (letter) Oral pilocarpine hydrochloride for the treatment of refractory

S. Singhal, J. Mehta, R. Powles, 2011 .

Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies.

S. Singhal, J. Mehta, R. Powles, 1997, Leukemia & lymphoma.

Oral pilocarpine hydrochloride for the treatment of refractory xerostomia associated with chronic graft-versus-host disease.

S. Singhal, J. Mehta, R. Powles, 1995, Blood.

Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients

L. Gordon, J. Winter, S. Singhal, 2007, Cancer.

Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse.

S. Singhal, J. Mehta, R. Powles, 1999, Leukemia & lymphoma.

Kinetics of paraprotein clearance after autografting for multiple myeloma.

S. Singhal, J. Mehta, D. Cunningham, 1995, Bone marrow transplantation.

Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors.

S. Singhal, J. Mehta, D. Tait, 1995, Bone marrow transplantation.

High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission

S. Singhal, J. Mehta, B. Sirohi, 2004, Bone Marrow Transplantation.

Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: long-term follow-up.

S. Singhal, J. Mehta, G. Hale, 1996, Leukemia & lymphoma.

Renal dysfunction following autologous bone marrow transplantation in adult patients with acute leukemia.

S. Singhal, J. Mehta, D. Tait, 1996, Acta oncologica.

Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: a little methotrexate goes a long way.

S. Singhal, J. Mehta, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A descriptive audit of healthcare workers exposed to COVID‐19 at a tertiary care center in India

S. Singhal, S. Kumari, P. Ranjan, 2021, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

D. Esseltine, B. Barlogie, P. Wen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Infection – an underappreciated cause of bone pain in multiple myeloma

B. Barlogie, S. Jagannath, N. Munshi, 2003, British journal of haematology.

Breakthrough Fungal Infections after Allogeneic Hematopoietic Stem Cell Transplantation in Patients on Prophylactic Voriconazole.

L. Gordon, J. Winter, S. Singhal, 2006 .

A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema.

S. Singhal, J. Guitart, J. Swan, 2004, Journal of the American Academy of Dermatology.

Aplastic crisis and leg ulceration: two rare complications of hereditary sideroblastic anaemia.

S. Singhal, J. Mehta, B. Mehta, 1992, The Journal of the Association of Physicians of India.

Non-myeloablative allogeneic transplantation (‘microallograft’) for refractory myeloma after two preceding autografts: feasibility and efficacy in a patient with active aspergillosis

S. Singhal, J. Mehta, P. Henslee-Downey, 2000, Bone Marrow Transplantation.

Evaluation of amnion in creation of neovagina in women with Mayer-Rokitansky-Kuster-Hauser syndrome.

S. Singhal, Neeta Singh, K. Roy, 2017, Fertility and sterility.

Cytomegaloviremia after autografting for leukemia: clinical significance and lack of effect on engraftment

S. Singhal, J. Mehta, C. Pinkerton, 1997, Leukemia.

Molecular Analysis of Burkholderia (Pseudomonas) cepacia: Differentiation Between Relapse and Reinfection in a Case of Recurrent Bacteremia

S. Singhal, J. Mehta, Jenny C. Chang, 1996 .

Multiple myeloma

S. Singhal, C. Huff, G. Tricot, 2001, Bone Marrow Transplantation.

Counselling of an RPL Couple

S. Singhal, J. Bharti, 2018 .

Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 × 109/l neutrophils on 3 consecutive days to define myeloid recovery

J. Winter, S. Singhal, J. Mehta, 2002, Bone Marrow Transplantation.

Early identification of patients at risk of death due to infections, hemorrhage, or graft failure after allogeneic bone marrow transplantation on the basis of the leukocyte counts

S. Singhal, J. Mehta, G. Middleton, 1997, Bone Marrow Transplantation.

Autoantibodies in thalassaemia major: relationship with oral iron chelator L1.

S. Singhal, J. Mehta, R. Reporter, 1993, The Journal of the Association of Physicians of India.

Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin

S. Singhal, N. Raje, S. Rosen, 2014, Clinical Cancer Research.

Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma – a phase I/II feasibility and tolerance study of 17 patients

S. Singhal, J. Mehta, N. Raje, 2000, Bone Marrow Transplantation.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

C. Hofmeister, A. Krishnan, S. Singhal, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer

S. Singhal, J. Mehta, J. Greally, 2010, Wiley interdisciplinary reviews. Systems biology and medicine.

Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single center.

S. Singhal, J. Mehta, D. Tait, 1995, Bone marrow transplantation.

Predictors of chemotherapy resistance & relapse in gestational trophoblastic neoplasia

S. Singhal, L. Kumar, N. Bhatla, 2020, The Indian journal of medical research.

Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy.

S. Singhal, N. Krett, S. Rosen, 2012, Blood.

Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia

S. Singhal, J. Mehta, M. Tallman, 2006, Bone Marrow Transplantation.

Bortezomib-induced tumor lysis syndrome in multiple myeloma.

D. Esseltine, S. Singhal, J. Mehta, 2006, Clinical lymphoma & myeloma.

Identification of New Nonrandom Translocations in Multiple Myeloma With Multicolor Spectral Karyotyping

B. Barlogie, J. Shaughnessy, D. Siegel, 1998 .

Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping.

B. Barlogie, J. Shaughnessy, N. Munshi, 1998, Blood.

Endometrial Amoebiasis: A Rare Cause of Postmenopausal Vaginal Discharge

S. Singhal, R. Arora, Anil Jain, 2014 .

Recurrent Vaginal Cuff Dehiscence in a Treated Case of Carcinoma Cervix.

S. Singhal, D. Sharma, Sunesh Kumar, 2017, Journal of clinical and diagnostic research : JCDR.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Bart Barlogie, Gordan Srkalovic, David Irwin, 2003, The New England journal of medicine.

Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2006, British journal of haematology.

Appendicitis in Postpartum Period: A Diagnostic Challenge.

S. Singhal, R. Arora, D. Wadhawan, 2015, Journal of clinical and diagnostic research : JCDR.

Targeting Glucose Consumption and Autophagy in Myeloma with the Novel Nucleoside Analogue 8-Aminoadenosine*

S. Singhal, J. Qian, V. Gandhi, 2009, The Journal of Biological Chemistry.

Long-term outcome of adult acute leukemia patients who are alive and well 2 years after autologous blood or marrow transplantation

S. Singhal, J. Mehta, R. Powles, 1999, Bone Marrow Transplantation.

Red cell fragmentation (schistocytosis) after bone marrow transplantation

S. Singhal, J. Mehta, J. Treleaven, 1998, Bone Marrow Transplantation.

A Pilot Study Comparing Hysteroscopic Adhesiolysis by Conventional Resectoscope Versus Mini-resectoscope.

S. Singhal, P. Vanamail, K. Roy, 2017, Oman medical journal.

A Prospective Randomized Comparative Clinical trial of Hysteroscopic Septal Resection Using Conventional Resectoscope Versus Mini-resectoscope

S. Singhal, K. Roy, R. Zangmo, 2021, Journal of human reproductive sciences.

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2005, Cancer.

Men as partners in maternal health: an analysis of male awareness and attitude

S. Singhal, H. Narang, 2013 .

Updates to the NCCN Guidelines

A. Krishnan, S. Singhal, C. Huff, 2013 .

Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease

S. Singhal, J. Mehta, B. Sirohi, 2003, Bone Marrow Transplantation.

Thalidomide in Cancer

S. Singhal, J. Mehta, 2002, BioDrugs.

Thalidomide in cancer: potential uses and limitations.

S. Singhal, J. Mehta, 2001, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

Fatal systemic lupus erythematosus in patient taking oral iron chelator L1

S. Singhal, J. Mehta, B. Mehta, 1991, The Lancet.

Top Information Need Priorities of Older Adults Newly Diagnosed With Active Myeloma.

S. Singhal, D. Berry, K. Schepp, 2015, Journal of the advanced practitioner in oncology.

NCCN task force: clinical utility of PET in a variety of tumor types.

R. Coleman, S. Singhal, R. J. Lee, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.

S. Singhal, J. Mehta, D. Tait, 1996, Bone marrow transplantation.

Acute myeloid leukaemia Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?

S. Singhal, J. Mehta, D. Tait, 2002 .

Does donor–recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?

S. Singhal, J. Mehta, D. Tait, 2002, Bone Marrow Transplantation.

Age is not a prognostic variable with autotransplants for multiple myeloma.

B. Barlogie, D. Siegel, S. Singhal, 1999, Blood.

Total therapy with tandem transplants for newly diagnosed multiple myeloma.

B. Barlogie, B. Cheson, S. Jagannath, 1999, Blood.

Multicolor Spectral Karyotyping Identification of New Nonrandom Translocations in Multiple Myeloma With

B. Barlogie, J. Shaughnessy, D. Siegel, 2011 .

DEATHS IN PATIENTS RECEIVING ORAL IRON CHELATOR L1

S. Singhal, J. Mehta, B. Mehta, 1993, British journal of haematology.

Oral iron chelator L1 and autoimmunity.

S. Singhal, J. Mehta, B. Mehta, 1993, Blood.

Deferiprone in iron overload.

S. Singhal, J. Mehta, B. Mehta, 1995, New England Journal of Medicine.

Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation.

S. Singhal, J. Mehta, R. Powles, 1998, Blood.

Long-term safety of GM-CSF (molgramostim) administration after allogeneic bone marrow transplantation for hematologic malignancies: five-year follow-up of a double-blind randomized placebo-controlled study.

S. Singhal, J. Mehta, R. Powles, 1997, Leukemia & lymphoma.

Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility.

S. Singhal, J. Mehta, R. Powles, 1996, Bone marrow transplantation.

Erratum: Antitumor activity of thalidomide in refractory multiple myeloma (New England Journal of Medicine (November 18, 1999) 341 (1565-1571))

B. Barlogie, D. Siegel, N. Munshi, 2000 .

Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women.

S. Singhal, J. Mehta, G. Swansbury, 1996, Bone marrow transplantation.

Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation

L. Gordon, J. Winter, S. Singhal, 2009, Leukemia & lymphoma.

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation

L. Gordon, J. Winter, S. Singhal, 2006, Bone Marrow Transplantation.

Antimicrobial prophylaxis to prevent opportunistic infections in patients with chronic lymphocytic leukemia after allogeneic blood or marrow transplantation.

S. Singhal, J. Mehta, D. Catovsky, 1997, Leukemia & lymphoma.

Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells

J. Winter, S. Singhal, J. Mehta, 2002, Bone Marrow Transplantation.

Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy

S. Singhal, J. Mehta, J. Treleaven, 1997, Bone Marrow Transplantation.

Partially mismatched related donor bone marrow transplantation as salvage for patients with AML who failed autologous stem cell transplant

S. Singhal, S. Adams, F. Rhee, 2001, Bone Marrow Transplantation.

T cell-depleted allogeneic bone marrow transplantation from a partially HLA-mismatched unrelated donor for progressive chronic lymphocytic leukemia and fludarabine-induced bone marrow failure.

S. Singhal, J. Mehta, D. Catovsky, 1996, Bone marrow transplantation.

Foscarnet therapy for cytomegalovirus infection after allogeneic bone marrow transplantation.

S. Singhal, J. Mehta, J. Chang, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia.

S. Singhal, J. Mehta, D. Catovsky, 1996, Bone marrow transplantation.

Three weeks of ganciclovir for cytomegaloviraemia after allogeneic bone marrow transplantation.

S. Singhal, J. Mehta, R. Powles, 1995, Bone marrow transplantation.

Unusual infections following allogeneic bone marrow transplantation for chronic lymphocytic leukemia.

S. Singhal, J. Mehta, D. Catovsky, 1994, Bone marrow transplantation.

Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?

J. Winter, S. Singhal, J. Mehta, 2005, Bone Marrow Transplantation.

Stem cell mobilization Can the stem cell mobilization technique influence CD34 þ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies

L. Gordon, J. Winter, S. Singhal, 2005 .

CD34+ cell collection efficiency does not correlate with the pre-leukapheresis hematocrit

J. Winter, S. Singhal, J. Mehta, 2001, Bone Marrow Transplantation.

Comparison of Cobe Spectra and Haemonetics MCS-3P cell separators for peripheral blood stem cell harvesting.

S. Singhal, J. Mehta, R. Morilla, 1995, Bone marrow transplantation.

Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?

L. Gordon, J. Winter, S. Singhal, 2003, Bone Marrow Transplantation.

Prospective, concurrent comparison of the Cobe Spectra and Haemonetics MCS‐3P cell separators for leukapheresis after high‐dose filgrastim in patients with hematologic malignancies

S. Singhal, J. Mehta, V. Shepherd, 1997, Journal of clinical apheresis.

Outcome of autologous rescue after failed engraftment of allogeneic marrow.

S. Singhal, J. Mehta, R. Powles, 1996, Bone marrow transplantation.

Oral iron chelator L1 and autoimmunity [letter; comment]

S. Singhal, J. Mehta, Mehta Bc, 1993 .

Failure of cyclosporine to induce graft-vs-host disease or graft-vs-leukemia after syngeneic bone marrow transplantation in mice.

S. Singhal, J. Mehta, S. Slavin, 1996, Leukemia research.

Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product.

L. Gordon, J. Winter, S. Singhal, 2015, Clinical lymphoma, myeloma & leukemia.

Number of nucleated cells infused during allogeneic and autologous bone marrow transplantation: an important modifiable factor influencing outcome.

S. Singhal, J. Mehta, R. Powles, 1997, Blood.

Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?

J. Winter, S. Singhal, J. Mehta, 2009, Bone Marrow Transplantation.

Treatment of multiple myeloma

S. Singhal, 2003, BMJ : British Medical Journal.

Expansion of a clonal CD8+CD57+ large granular lymphocyte population after autologous stem cell transplant in multiple myeloma.

S. Singhal, A. Chenn, K. Wolniak, 2013, American journal of clinical pathology.

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci

J. Witte, M. Lieber, G. Colditz, 2016, Cancer Epidemiology, Biomarkers & Prevention.

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation

L. Gordon, J. Winter, S. Singhal, 2006, Bone Marrow Transplantation.

The CD34+ Cell Dose, Even in an "Acceptable" Range, Affects Outcome of Allogeneic Blood Stem Cell Transplantation.

L. Gordon, J. Winter, S. Singhal, 2004 .

The role of autologous transplantation in patients with multiple myeloma aged 65 years and over

S. Singhal, J. Mehta, H. Pandha, 2000, Bone Marrow Transplantation.

Factors affecting engraftment and hematopoietic recovery after unpurged autografting in acute leukemia.

S. Singhal, J. Mehta, R. Powles, 1996, Bone marrow transplantation.

Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients

S. Singhal, J. Mehta, R. Powles, 1997, Bone Marrow Transplantation.

Leukocyte recovery and early treatment-related mortality after bone marrow transplantation.

S. Singhal, J. Mehta, R. Powles, 1997, Blood.

Letter to the editor: Low‐dose cyclosporin for severe aplastic anemia

S. Singhal, J. Mehta, B. Mehta, 1992 .

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

A. Krishnan, S. Singhal, Rashmi Kumar, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

J. Witte, G. Colditz, A. Olshan, 2020, Blood advances.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

A. Jakubowiak, A. Krishnan, S. Lonial, 2016, The Lancet.

The implication of compromised renal function at presentation in myeloma

S. Singhal, J. Mehta, N. Raje, 2001, Medical oncology.

First thalidomide clinical trial in multiple myeloma: a decade.

B. Barlogie, J. Shaughnessy, S. Jagannath, 2008, Blood.

Multiple myeloma, version 1.2013.

A. Krishnan, S. Singhal, Rashmi Kumar, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Safety and Efficacy of Bortezomib in Multiple Myeloma Patients with Renal Failure Requiring Dialysis.

S. Jagannath, S. Lonial, S. Singhal, 2005 .

A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long‐term follow‐up in newly diagnosed mantle cell lymphoma

A. Rademaker, L. Gordon, J. Winter, 2008, British journal of haematology.

Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

B. B. Weitner, A. Rademaker, L. Gordon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reassessing autotransplantation for acute myeloid leukaemia in first remission – a matched pair analysis of autologous marrow vs peripheral blood stem cells

S. Singhal, J. Mehta, M. Labopin, 2004, Bone Marrow Transplantation.

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

David E. Irwin, S. Jagannath, S. Singhal, 2009, Blood.

Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation.

S. Singhal, J. Mehta, D. Tait, 1995, Bone marrow transplantation.

Melphalan Versus Cyclophosphamide with Total-Body Irradiation as Conditioning for Allogeneic Bone-Marrow Transplantation in 1St Remission Acute Myeloid-Leukemia

S. Singhal, J. Mehta, Jenny C. Chang, 1994 .

Uterine artery embolization: exploring new dimensions in obstetric emergencies.

S. Singhal, U. Gupta, A. Singh, 2014, Oman medical journal.

Beneficial Effects of Hematopoietic Growth Factor Therapy in Chronic Ischemic Stroke in Rats

A. Apkarian, S. Singhal, J. Mehta, 2007, Stroke.

Brain Repair by Hematopoietic Growth Factors in a Rat Model of Stroke

S. Singhal, J. Mehta, Li-Ru Zhao, 2007, Stroke.

Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma

S. Singhal, N. Krett, S. Rosen, 2008, The Journal of Steroid Biochemistry and Molecular Biology.

Impact of injectable progestogen contraception in early puerperium on lactation and infant health.

S. Singhal, Shipra Gupta, Nivedita Sarda, 2014, Journal of clinical and diagnostic research : JCDR.

A rare case of Meckel-Gruber syndrome : Antenatal diagnosis

S. Singhal, N. Gupta, 2017 .

Myelosuppressive chemotherapy to mobilize normal stem cells in chronic myeloid leukemia.

S. Singhal, J. Mehta, B. Czepulkowski, 1996, Bone marrow transplantation.

preemptive ganciclovir or foscarnet (letter; comment) Prevention of cytomegalovirus disease by a short course of

S. Singhal, J. Mehta, R. Powles, 2012 .

Prevention of cytomegalovirus disease by a short course of preemptive ganciclovir or foscarnet.

S. Singhal, J. Mehta, R. Powles, 1994, Blood.

Multiple myeloma. Clinical practice guidelines in oncology.

J. Vose, S. Singhal, C. Huff, 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma.

S. Singhal, J. Mehta, N. Raje, 1997, British Journal of Cancer.

Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma

B. Barlogie, D. Siegel, S. Singhal, 1999 .

How I treat elderly patients with myeloma.

S. Singhal, J. Mehta, M. Cavo, 2010, Blood.

How I treat How I treat elderly patients with myeloma

S. Singhal, J. Mehta, M. Cavo, 2010 .

High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years

S. Singhal, J. Mehta, 2007, Bone Marrow Transplantation.

Recent developments and future directions in the treatment of multiple myeloma.

S. Singhal, J. Mehta, D. Pichardo, 2003, Cancer biotherapy & radiopharmaceuticals.

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

R. Vij, S. Singhal, S. Ely, 2015, Leukemia & lymphoma.

Allogeneic and autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non-Hodgkin lymphoma

L. Gordon, J. Winter, S. Singhal, 2013 .

Glomerular filtration rate prior to high-dose melphalan 200 mg/m2as a surrogate marker of outcome in patients with myeloma

S. Singhal, J. Mehta, B. Sirohi, 2001, British Journal of Cancer.

Treatment of relapsed and refractory multiple myeloma

S. Singhal, J. Mehta, 2003, Current treatment options in oncology.

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

F. Zhan, S. Jagannath, A. Jakubowiak, 2011, European journal of haematology.

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

A. Krishnan, S. Singhal, A. Chanan-Khan, 2019, Blood Cancer Journal.

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.

S. Singhal, F. van Rhee, J. Zonder, 2012, Blood.

Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma

S. Singhal, J. Mehta, B. Sirohi, 2002, Bone Marrow Transplantation.

Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system

S. Singhal, J. Mehta, N. Raje, 1999, British journal of haematology.

Allogeneic bone marrow transplantation for primary myelofibrosis.

S. Singhal, J. Mehta, C. Pollard, 1995, Bone marrow transplantation.

Current status of autologous hematopoietic stem cell transplantation in myeloma

S. Singhal, J. Mehta, 2008, Bone Marrow Transplantation.

Multiple myeloma.

S. Singhal, J. Mehta, 2006, Clinical journal of the American Society of Nephrology : CJASN.

Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-α therapy

B. Barlogie, S. Singhal, J. Mehta, 1999, Bone Marrow Transplantation.

An elective single autograft with high-dose melphalan: single-center study of 451 patients

S. Singhal, J. Mehta, B. Sirohi, 2005, Bone Marrow Transplantation.

A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C‐VAMP) as induction treatment followed by autografting in previously untreated myeloma

S. Singhal, J. Mehta, D. Cunningham, 1997, British journal of haematology.

Novel Therapies in Multiple Myeloma

S. Singhal, J. Mehta, 2003, International journal of hematology.

Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment

S. Singhal, J. Mehta, M. Gore, 1997, Bone Marrow Transplantation.

Lenalidomide in Myeloma

S. Singhal, J. Mehta, 2007, Current treatment options in oncology.

Hematopoietic reconstitution by transplantation of stem cells from bone marrow or blood.

S. Singhal, J. Mehta, R. Powles, 2001, The New England journal of medicine.

Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.

A. Rademaker, L. Gordon, J. Winter, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose hydroxyurea and G-CSF to collect Philadelphia-negative cells in chronic myeloid leukemia: preliminary results.

S. Singhal, J. Mehta, T. Min, 1996, Leukemia & lymphoma.

Advances in the treatment of multiple myeloma.

B. Barlogie, S. Singhal, J. Mehta, 1997, Current opinion in hematology.

Granulocyte‐colony stimulating factor administration after myocardial infarction in a porcine ischemia‐reperfusion model: Functional and pathological effects of dose timing

Edwin Wu, Daniel C. Lee, Jayesh Mehta, 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Reappearance of a Glomus tumor of the finger after nine years- A rare case report and literature review

Raju Vaishya, S. Singhal, A. Vaish, 2022, Journal of Orthopaedic Reports.

Giant-cell tumor of the metacarpal in a young female: A rare case report

S. Singhal, C. Shekhar, 2020 .

Impact of energy devices on the post-operative systemic immune response in women undergoing total laparoscopic hysterectomy for benign disease of the uterus

S. Singhal, D. Mitra, P. Vanamail, 2018, Journal of the Turkish German Gynecological Association.

An Analysis of Factors Affecting the Duration of Latency Period and Its Impact on Neonatal Outcome in Patients with PPROM

S. Singhal, M. Puri, K. Rao, 2012 .

National screening programs for cervical cancer in Asian countries

S. Singhal, K. Saika, N. Bhatla, 2020, Journal of gynecologic oncology.

Role of pelvic and para-aortic lymphadenectomy in epithelial ovarian cancers

S. Singhal, L. Kumar, S. Mathur, 2019 .

Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue.

S. Singhal, J. Mehta, D. Cunningham, 1995, Stem cells.

Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea

J. Winter, S. Singhal, J. Mehta, 2002, Bone Marrow Transplantation.

Older adults newly diagnosed with symptomatic myeloma and treatment decision making.

Joseph D Tariman, S. Singhal, D. Berry, 2014, Oncology nursing forum.

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

A. Krishnan, S. Singhal, A. Chanan-Khan, 2019, Blood Cancer Journal.

The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios.

S. Singhal, J. Mehta, V. Singh, 2009, Blood.

The Relationship Between Serum Free Light Chain Levels and Serum Immunofixation Electrophoresis: Implications for the Definition of “Stringent CR” in Myeloma

S. Singhal, J. Mehta, Eric Vickrey, 2008 .

A Phase II Study of PXD101 in Advanced Multiple Myeloma.

S. Singhal, A. Waage, M. Schuster, 2006 .

Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission.

S. Singhal, J. Mehta, D. Tait, 1996, Bone marrow transplantation.

Melphalan and total-body irradiation as a conditioning regimen for autologous bone marrow transplantation in acute myeloid leukemia.

S. Singhal, J. Mehta, D. Tait, 1995 .

Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States.

G. Colditz, C. Haiman, D. Auclair, 2020, JCO oncology practice.

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

P. L. Bergsagel, S. Trudel, S. Singhal, 2012 .

Rigorous administration of methotrexate and outcome of allogeneic blood stem cell transplantation

S. Singhal, J. Mehta, 2007, Bone Marrow Transplantation.

HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS)

G. Colditz, C. Haiman, L. Kolonel, 2016 .

Localization of glutamate in the human retina during early prenatal development

S. Singhal, T. Nag, G. Jotwani, 1998, Journal of Biosciences.

Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria

S. Singhal, J. Mehta, B. Sirohi, 2001, Bone Marrow Transplantation.

Phase 1b Evaluation of the Safety and Efficacy of a 30-Minute IV Infusion of Carfilzomib In Patients with Relapsed and/or Refractory Multiple Myeloma

E. Sausville, D. Siegel, S. Singhal, 2010 .

90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.

A. Rademaker, L. Gordon, J. Winter, 2006 .

Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).

A. Krishnan, S. Singhal, A. Belch, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regression of cardiac amyloid after autologous stem-cell transplantation.

S. Singhal, J. Mehta, John E A Blair, 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Screening and management of preinvasive lesions of the cervix: Good clinical practice recommendations from the Federation of Obstetrics and Gynaecologic Societies of India (FOGSI)

S. Singhal, N. Bhatla, P. Basu, 2019, The journal of obstetrics and gynaecology research.

Phase I Study of Elotuzumab (HuLuc63) in Phase I Study of Elotuzumab (HuLuc63) in Relapsed/Refractory Multiple Myeloma

N. Munshi, S. Singhal, J. Zonder, 2008 .

Phase I Trial of HuLuc63 in Multiple Myeloma.

N. Munshi, S. Singhal, J. Zonder, 2007 .

Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy.

S. Singhal, J. Mehta, T. Hickish, 1996, Leukemia & lymphoma.

Clinical profile & outcome of H1N1 infected pregnant women in a tertiary care teaching hospital of northern India

S. Singhal, R. Arora, Anil Jain, 2014, The Indian journal of medical research.

Double blinded study on comparison of phosphorylated insulin like growth factor binding protein 1 test and fetal fibronectin test for prediction of preterm delivery

S. Singhal, Nivedita Sarda, Kusum Dogra, 2017 .

Cyclophosphamide-induced cardiomyopathy during bone marrow transplantation for severe aplastic anemia.

S. Singhal, J. Mehta, R. Or, 1994, The Journal of the Association of Physicians of India.

A clinicopathological study of granulosa cell tumors of the ovary: Can morphology predict prognosis?

S. Singhal, L. Kumar, S. Mathur, 2020, Indian journal of pathology & microbiology.

Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-α2b

S. Singhal, J. Mehta, R. Powles, 1997, Bone Marrow Transplantation.

Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.

S. Singhal, J. Mehta, P. Glynne, 1996, Seminars in hematology.

Study of laboratory parameters in COVID-19 patients at a tertiary care teaching hospital in Uttar Pradesh

S. Singhal, P. Singhal, S. Puri, 2021, Acta Medica International.

Final analysis of MM-014: Single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

S. Jagannath, S. Singhal, P. Richardson, 2008 .

A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.

Michael L. Wang, A. Jakubowiak, S. Lonial, 2007, Clinical advances in hematology & oncology : H&O.

Black box warning on lenalidomide-associated venous thromboembolism (VTE) in off-label setting: A preemptive and unusual safety initiative.

S. Singhal, J. Mehta, P. Yarnold, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TREATMENT OF SEVERE APLASTIC ANAEMIA WITH TOTAL LYMPHOID IRRADIATION AND METHYLPREDNISOLONE

S. Singhal, J. Mehta, N. Huilgol, 1992, British journal of haematology.

SUBACUTE SCLEROSING PANENCEPHALITIS: A RARE NEUROLOGICAL DISORDER IN PREGNANCY

S. Singhal, M. Rana, V. M. Rana, 2015 .

Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

S. Jagannath, A. Jakubowiak, S. Lonial, 2011 .

PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis.

S. Jagannath, A. Jakubowiak, S. Lonial, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM).

D. Siegel, S. Singhal, P. Hari, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Uterine tumor resembling ovarian sex cord tumor: A series of six cases displaying varied histopathological patterns and clinical profiles

S. Singhal, M. Sharma, S. Mathur, 2020, Indian journal of pathology & microbiology.

Central nervous system relapse after bone marrow transplantation for acute leukemia in first remission.

S. Singhal, J. Mehta, D. Tait, 1996, Bone Marrow Transplantation.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

A. Krishnan, S. Singhal, Rashmi Kumar, 2012, The Journal of the National Comprehensive Cancer Network.

Factor VII inhibitor.

S. Singhal, J. Mehta, B. Mehta, 1992, Journal of Association of Physicians of India.

Retrospective analysis of surgically treated cases of squamous cell carcinoma vulva

S. Singhal, D. Sharma, J. Bharti, 2021, Journal of Cancer Research and Therapeutics.

Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.

A. Jakubowiak, S. Lonial, Jeffrey N. Martin, 2007 .

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

C. Hofmeister, A. Krishnan, S. Singhal, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Erratum: Myeloma management guidelines: A consensus report from the scientific advisors of the international myeloma foundation (The Hematology Journal (2003) vol, 4 (379-398) 10.1038/sj.thj.6200312)

G. Morgan, P. Sonneveld, J. Miguel, 2004 .

Conflicts of interest, authorship, and disclosures in industry-related scientific publications.

B. Barlogie, J. Shaughnessy, R. Fonseca, 2010, Mayo Clinic proceedings.

An approach to diagnosis and management of acute fatty liver of pregnancy

S. Singhal, M. Puri, N. Gami, 2013 .

Osteonecrosis of the Jaw in Myeloma Patients Receiving Pamidronate or Zoledronate.

Joseph D Tariman, S. Singhal, J. Mehta, 2004 .

Low-Dose Recombinante Urate Oxidase (Rasburicase) Is Effective in Treating Hyperuricemia in Patients with Hematologic Malignancies.

L. Gordon, S. Singhal, J. Mehta, 2005 .

Low-Dose Recombinante Urate Oxidase (Rasburicase) Is Effective in Hyperuricemia.

L. Gordon, S. Singhal, J. Mehta, 2004 .

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

Megan C. Manco, J. Leonard, S. Singhal, 2009 .

Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy

S. Singhal, J. Mehta, Eric Vickrey, 2009, Cancer.

First thalidomide clinical trial in multiple myeloma: a decade.

B. Barlogie, J. Shaughnessy, S. Jagannath, 2008, Blood.